{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,7]],"date-time":"2026-06-07T09:29:04Z","timestamp":1780824544280,"version":"3.54.1"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,4,8]],"date-time":"2021-04-08T00:00:00Z","timestamp":1617840000000},"content-version":"am","delay-in-days":342,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100007601","name":"Horizon 2020","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007601","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Antiviral Research"],"published-print":{"date-parts":[[2020,5]]},"DOI":"10.1016\/j.antiviral.2020.104758","type":"journal-article","created":{"date-parts":[[2020,3,2]],"date-time":"2020-03-02T04:11:39Z","timestamp":1583122299000},"page":"104758","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Ribavirin does not potentiate favipiravir antiviral activity against Ebola virus in non-human primates"],"prefix":"10.1016","volume":"177","author":[{"given":"Vincent","family":"Madelain","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aur\u00e9lie","family":"Duthey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"France","family":"Mentr\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fr\u00e9d\u00e9ric","family":"Jacquot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Solas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Lacarelle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Audrey","family":"Vallv\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phane","family":"Barron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Barrot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phanie","family":"Mundweiler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damien","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Carbonnelle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herv\u00e9","family":"Raoul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"de Lamballerie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e9r\u00e9mie","family":"Guedj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.antiviral.2020.104758_bib1","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1128\/JVI.02701-15","article-title":"Determination and therapeutic exploitation of Ebola virus spontaneous mutation frequency","volume":"90","author":"Alfson","year":"2016","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2020.104758_bib2","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1086\/657315","article-title":"Review of the literature and proposed guidelines for the use of oral ribavirin as postexposure prophylaxis for Lassa fever","volume":"51","author":"Bausch","year":"2010","journal-title":"Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am."},{"key":"10.1016\/j.antiviral.2020.104758_bib3","doi-asserted-by":"crossref","DOI":"10.3389\/fpubh.2016.00222","article-title":"Effects of the West Africa Ebola virus disease on health-care utilization \u2013 a systematic review","volume":"4","author":"Brolin Ribacke","year":"2016","journal-title":"Front. Publ. Health"},{"key":"10.1016\/j.antiviral.2020.104758_bib4","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/0041-008X(84)90139-X","article-title":"Hematological and bone marrow effects of ribavirin in rhesus monkeys","volume":"74","author":"Canonico","year":"1984","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.antiviral.2020.104758_bib5","doi-asserted-by":"crossref","first-page":"3444","DOI":"10.1128\/AAC.00372-06","article-title":"Ribavirin antagonizes the in vitro anti-hepatitis C virus activity of 2\u2019-C-methylcytidine, the active component of valopicitabine","volume":"50","author":"Coelmont","year":"2006","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2020.104758_bib6","doi-asserted-by":"crossref","first-page":"4713","DOI":"10.1200\/JCO.2002.02.140","article-title":"Model of chemotherapy-induced myelosuppression with parameter consistency across drugs","volume":"20","author":"Friberg","year":"2002","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.antiviral.2020.104758_bib7","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1128\/AAC.49.3.981-986.2005","article-title":"Mechanism of action of T-705 against influenza virus","volume":"49","author":"Furuta","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2020.104758_bib8","doi-asserted-by":"crossref","first-page":"449","DOI":"10.2183\/pjab.93.027","article-title":"Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase","volume":"93","author":"Furuta","year":"2017","journal-title":"Proc. Jpn. Acad. Ser. B Phys. Biol. Sci."},{"key":"10.1016\/j.antiviral.2020.104758_bib9","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002535","article-title":"Antiviral efficacy of favipiravir against Ebola virus: a translational study in cynomolgus macaques","volume":"15","author":"Guedj","year":"2018","journal-title":"PLoS Med."},{"key":"10.1016\/j.antiviral.2020.104758_bib10","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1093\/infdis\/149.3.420","article-title":"Enhanced treatment of Lassa fever by immune plasma combined with ribavirin in cynomolgus monkeys","volume":"149","author":"Jahrling","year":"1984","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2020.104758_bib11","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1208\/s12248-012-9368-z","article-title":"Population pharmacokinetics and pharmacodynamics of ribavirin in patients with chronic hepatitis C genotype 1 infection","volume":"14","author":"Jin","year":"2012","journal-title":"AAPS J."},{"key":"10.1016\/j.antiviral.2020.104758_bib12","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1128\/AAC.47.1.124-129.2003","article-title":"Ribavirin quantification in combination treatment of chronic hepatitis C","volume":"47","author":"Larrat","year":"2003","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2020.104758_bib13","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1128\/AAC.47.4.1395-1398.2003","article-title":"Pharmacokinetics and metabolism of [14C]ribavirin in rats and cynomolgus monkeys","volume":"47","author":"Lin","year":"2003","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2020.104758_bib14","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1007\/s10928-012-9261-5","article-title":"Modeling of red blood cell life-spans in hematologically normal populations","volume":"39","author":"Lled\u00f3-Garc\u00eda","year":"2012","journal-title":"J. Pharmacokinet. Pharmacodyn."},{"key":"10.1016\/j.antiviral.2020.104758_bib15","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.jchromb.2007.05.039","article-title":"Measurement of ribavirin and evaluation of its stability in human plasma by high-performance liquid chromatography with UV detection","volume":"856","author":"Loregian","year":"2007","journal-title":"J. Chromatogr. B"},{"key":"10.1016\/j.antiviral.2020.104758_bib16","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01305-16","article-title":"Favipiravir pharmacokinetics in nonhuman primates and insights for future efficacy studies of hemorrhagic fever viruses","volume":"61","author":"Madelain","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2020.104758_bib17","doi-asserted-by":"crossref","first-page":"4013","DOI":"10.1038\/s41467-018-06215-z","article-title":"Ebola viral dynamics in nonhuman primates provides insights into virus immuno-pathogenesis and antiviral strategies","volume":"9","author":"Madelain","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.antiviral.2020.104758_bib18","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1177\/135965350501000217","article-title":"In vitro combination studies of tenofovir and other nucleoside analogues with ribavirin against HIV-1","volume":"10","author":"Margot","year":"2005","journal-title":"Antivir. Ther."},{"key":"10.1016\/j.antiviral.2020.104758_bib19","doi-asserted-by":"crossref","DOI":"10.1038\/sdata.2014.42","article-title":"A comprehensive database of the geographic spread of past human Ebola outbreaks","volume":"1","author":"Mylne","year":"2014","journal-title":"Sci. Data"},{"key":"10.1016\/j.antiviral.2020.104758_bib20","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0005389","article-title":"Favipiravir pharmacokinetics in Ebola-Infected patients of the JIKI trial reveals concentrations lower than targeted","volume":"11","author":"Nguyen","year":"2017","journal-title":"PLoS Neglected Trop. Dis."},{"key":"10.1016\/j.antiviral.2020.104758_bib21","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0002804","article-title":"Evaluation of antiviral efficacy of ribavirin, arbidol, and T-705 (favipiravir) in a mouse model for Crimean-Congo hemorrhagic fever","volume":"8","author":"Oestereich","year":"2014","journal-title":"PLoS Neglected Trop. Dis."},{"key":"10.1016\/j.antiviral.2020.104758_bib22","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1093\/infdis\/jiv522","article-title":"Efficacy of favipiravir alone and in combination with ribavirin in a lethal, immunocompetent mouse model of Lassa fever","volume":"213","author":"Oestereich","year":"2016","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2020.104758_bib23","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.antiviral.2011.05.006","article-title":"Depletion of GTP pool is not the predominant mechanism by which ribavirin exerts its antiviral effect on Lassa virus","volume":"91","author":"\u00d6lschl\u00e4ger","year":"2011","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2020.104758_bib24","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.virusres.2004.11.006","article-title":"Metabolism and antiviral activity of ribavirin","volume":"107","author":"Parker","year":"2005","journal-title":"Virus Res."},{"key":"10.1016\/j.antiviral.2020.104758_bib25","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.antiviral.2017.01.017","article-title":"Implementation of a non-human primate model of Ebola disease: infection of Mauritian cynomolgus macaques and analysis of virus populations","volume":"140","author":"Piorkowski","year":"2017","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2020.104758_bib26","unstructured":"Japanese Pharmaceuticals and Medical Devices Agency (PMDA), n.d. reportReport on the Deliberation Results (English version)."},{"key":"10.1016\/j.antiviral.2020.104758_bib27","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1093\/cid\/cix406","article-title":"Favipiravir and ribavirin treatment of epidemiologically linked cases of Lassa fever","volume":"65","author":"Raabe","year":"2017","journal-title":"Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am."},{"key":"10.1016\/j.antiviral.2020.104758_bib28","doi-asserted-by":"crossref","first-page":"3351","DOI":"10.2174\/092986706778773059","article-title":"Ribavirin-induced anemia: mechanisms, risk factors and related targets for future research","volume":"13","author":"Russmann","year":"2006","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.antiviral.2020.104758_bib29","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1517\/17460441.2015.1035252","article-title":"Animal models for ebolavirus countermeasures discovery: what defines a useful model?","volume":"10","author":"Shurtleff","year":"2015","journal-title":"Expet Opin. Drug Discov."},{"key":"10.1016\/j.antiviral.2020.104758_bib30","article-title":"Experimental treatment with favipiravir for Ebola virus disease (the JIKI trial): a historically controlled, single-arm proof-of-concept trial in Guinea","volume":"13","author":"Sissoko","year":"2016","journal-title":"PLoS Med."},{"key":"10.1016\/j.antiviral.2020.104758_bib31","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.antiviral.2016.10.007","article-title":"Lassa and Ebola virus inhibitors identified using minigenome and recombinant virus reporter systems","volume":"136","author":"Welch","year":"2016","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2020.104758_bib32","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.antiviral.2015.12.006","article-title":"Low-dose ribavirin potentiates the antiviral activity of favipiravir against hemorrhagic fever viruses","volume":"126","author":"Westover","year":"2016","journal-title":"Antivir. Res."}],"container-title":["Antiviral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016635421930734X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016635421930734X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T12:31:56Z","timestamp":1759062716000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016635421930734X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5]]},"references-count":32,"alternative-id":["S016635421930734X"],"URL":"https:\/\/doi.org\/10.1016\/j.antiviral.2020.104758","relation":{},"ISSN":["0166-3542"],"issn-type":[{"value":"0166-3542","type":"print"}],"subject":[],"published":{"date-parts":[[2020,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ribavirin does not potentiate favipiravir antiviral activity against Ebola virus in non-human primates","name":"articletitle","label":"Article Title"},{"value":"Antiviral Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.antiviral.2020.104758","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"104758"}}